The call ran from 5:01 PM to 5:51 PM IST (50 min).
Key takeaways
Consolidated Q2 revenue rose 31%, but H1 organic growth was only 14%. Pendra Care is loss-making and Italy tenders are delayed. FY27 revenue guidance was reaffirmed and the standalone margin band raised.
| EBITDA Margin guidance | 26.0% → 26.8% Raised by 0.8 percentage points |
|---|---|
| Management target | Revenue 100.0% FY30 |
| Revenue growth | Consolidated Q2 +31% YoY; H1 organic +14%, acquisitions drive rest. |
|---|---|
| Margins | Gross margin 70.1% in Q2, down from 73.4% QoQ; Pendra Care loss-making. |
| Demand visibility | Europe Q2 organic ~40%; RoW down 7% on freight and West Asia. |
| Management confidence | Optimistic; reaffirms revenue guidance, raises standalone margin band. |
Growth
Consolidated Q2 revenue ₹581 Cr (+31% YoY), with acquisitions driving most of the gap versus 14% H1 organic growth.
Outlook
FY27 consolidated revenue ₹2,300–2,400 Cr reaffirmed; standalone EBITDA margin band raised to 26–27.5%.
Risks
Pendra Care is loss-making on Middle East exposure, Italy tender delays persist, and Chinese dialysis dumping remains unresolved.
Last quarter's promises, checked
Delivered
- Standalone EBITDA 25–27% → Q1 28%, band raised to 26–27.5% (= BEAT)
- Europe organic 17–18% → Q2 ~40% (= BEAT)
Partly delivered
- Consolidated revenue ₹2,300–2,400 Cr → Q1 ₹525 Cr, Q2 ₹581 Cr, reaffirmed (= PARTIAL)
- Capex ₹200–225 Cr → H1 ₹124 Cr (= PARTIAL)
- Consolidated EBITDA 23–25% → Q1 24%, Q2 not disclosed (= PARTIAL)
Missed
- Consolidated gross margin 71–72% → Q2 70.1% (= MISS)
- Middle East 20–25%+ growth once West Asia normalises → RoW down 7% (= MISS)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
The results behind this call
Poly Medicure Q2 FY27 Results: Net Profit ₹95.1 Cr, Up 3.6% YoY
Poly Medicure Ltd reported revenue from operations of ₹580.5 Cr (+30.8% YoY) and net profit of ₹95.1 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹95.1 Cr · +3.6% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Management aims to double revenue by FY30 via high-tech verticals and aggressive international direct-market expansion.
Growth they described
Consolidated revenue grew 30.3% YoY, heavily aided by the Pendrakare and CTF acquisitions.
Call details
| Company | Poly Medicure Ltd |
|---|---|
| NSE symbol | POLYMED |
| ISIN | INE205C01021 |
| Call | Q2 FY27 earnings call |
| Date | Thursday, 5 November 2026 |
| Time | 5:00 PM IST |
| Length | 50 min |
| Audio | Our stream on YouTube ↗ |
Poly Medicure Ltd: key numbers
- Share price
- ₹1,615.00
- Market cap
- ₹16,370 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 52.0×Sector 54.5×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Thu, 5 Nov
Today's concalls →
